

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Ritlecitinib 50 mg capsules (Litfulo)

Notes:

- Quantity Limits: Yes
- Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria, criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously, and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary ritlecitinib 50 mg capsules (Litfulo) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescriber is a dermatologist and patient has a diagnosis of alopecia areata
- Patient has at least 50% hair loss
- Patient is at least 12 years of age
- Patient has tried and failed/intolerant to squaric acid dibutyl ester
- Patient has tried and failed/intolerant to at least 3 of the following:
 - Intralesional steroids
 - Topical steroids
 - Methotrexate
 - Azathioprine
 - Cyclosporine
 - Sulfasalazine
 - Mycophenolate

Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Non-formulary ritlecitinib 50 mg capsules (Litfulo) will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescriber is a dermatologist
- Patient has responded to ritlecitinib as determined by prescriber